NCI-H295R Xenograft Model Service for Adrenal Cancer

Accelerate your breakthrough in adrenal cortical carcinoma research with our comprehensive NCI-H295R Xenograft Model Service for Adrenal Cancer, the definitive in vivo platform for evaluating novel therapeutics against this rare and aggressive malignancy. Alfa Cytology, a premier preclinical CRO specializing in oncology models, proudly offers full-service capabilities for NCI-H295R model development, validation, and efficacy testing, leveraging our state-of-the-art facilities and extensive expertise to deliver robust, reliable data that propels your drug discovery pipeline forward.

Overview of NCI-H295R Xenograft Model for Adrenal Cancer

The NCI-H295R cell line represents the gold standard in vitro model for studying Adrenocortical Carcinoma (ACC), a rare but devastating malignancy originating from the adrenal cortex. Derived from a female patient in the 1980s, NCI-H295R is uniquely valuable because it retains the dynamic steroidogenic capacity of the original tumor. It produces a broad spectrum of adrenal steroids, including mineralocorticoids, glucocorticoids, and androgens, making it an essential tool for researching the hormonal dysregulation characteristic of ACC.

When translated in vivo, the NCI-H295R Xenograft Model involves inoculating these characterized cells into immunodeficient mice (typically nude or SCID mice). The resulting tumors faithfully recapitulate many key features of human ACC, including rapid growth, invasive behavior, vascularization, and, crucially, the maintenance of a functional steroidogenic phenotype. This makes the model particularly suited for:

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting ACC.
• Mechanistic Studies: Investigating the complex molecular pathways driving ACC progression and steroidogenesis, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

The model provides a robust translational bridge, ensuring that promising in vitro findings are rigorously tested in a complex biological system before progressing to clinical trials.

Figure 1. MADCT-701 induces robust anti-tumor responses in DLK1+ ACC tumors. (Sun, et al., 2025)

Cell Line Information: NCI-H295R

The NCI-H295R cell line is a genetically stable, adherent cell line derived from the original NCI-H295 pluripotent human adrenocortical carcinoma cell line. Its ability to produce all three major classes of adrenal steroids in vitro makes it unique among available cell lines and essential for ACC research.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the NCI-H295R Xenograft Model Service. Our dedication to quality begins with the rigorous authentication and mycoplasma testing of the NCI-H295R cell line. We manage every critical step of the preclinical journey—from standardizing optimal inoculation parameters in validated immunodeficient strains to performing precision dosing, comprehensive in-life monitoring (including specialized steroid analysis), and detailed terminal endpoints.

Workflow of NCI-H295R Xenograft Model Construction

The successful construction of a reliable NCI-H295R xenograft model requires meticulous attention to detail and standardized procedures. At Alfa Cytology, we adhere to a optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Preparation: NCI-H295R cells are cultivated in vitro under strictly optimized conditions to reach exponential growth phase. Cells are harvested, washed, and resuspended in a cold, sterile vehicle (e.g., PBS) or, frequently, a 1:1 mixture with extracellular matrix (ECM) components like Matrigel to enhance tumor take and growth stability.
2. Animal Acclimatization: Health-certified, immunodeficient mice (e.g., Athymic Nude or SCID) are acclimatized to the facility conditions for at least one week prior to procedures.
3. Inoculation: Under aseptic conditions and appropriate anesthesia, a precise concentration of authenticated NCI-H295R cells (typically 5×106 to 1×107) is injected subcutaneously into the flank of each mouse.
4. Monitoring & Randomization: Mice are monitored daily for health and thrice weekly for tumor palpable growth. Once tumors reach a predetermined average volume (e.g., 100-200 mm³), the animals are randomized into treatment and control groups to ensure statistical balance.
5. Treatment & Evaluation: Dosing regimens (compound, vehicle, reference standard) commence according to the customized study protocol. Standard measurements include tumor volume (caliper measurement), body weight, and clinical observations throughout the study duration.

Figure 2: Schematic workflow illustrating the derivation and construction of the NCI-H295R Xenograft Model at Alfa Cytology.

Case Study-NCI-H295R Xenograft Model Development

Alfa Cytology has extensive experience in establishing the NCI-H295R model, optimizing protocols to achieve high model take rates and consistent, robust growth required for efficacy evaluation. In a representative development study, we compared different inoculation matrices and cell densities to define the parameters that yield the most reliable tumor growth kinetics. The data generated confirms our ability to deliver a standardized model suitable for rigorous drug testing. Comprehensive data showcasing growth curves, steroid hormone profiles, and histological validation under specialized conditions are available upon request to researchers.

Why Choose Alfa Cytology?

Choosing the right partner for your adrenal cancer research is critical given the complexity of the disease. Alfa Cytologystands out by offering specialized expertise and high-standard preclinical services:

• Verified Cell Line Integrity: We use only authenticated, mycoplasma-free NCI-H295R cells to ensure the biological relevance of your study.
• High Take Rates & Consistency: Our optimized inoculation protocols and matrix selections ensure reliable tumor development and reproducible growth curves.
• Comprehensive Analytical Support: Beyond tumor volume, we offer specialized assays for steroid hormone profiling (LC-MS/MS or ELISA) and detailed IHC staining.
• Tailored Study Designs: From initial dose-range finding (DRF) to complex combination therapy studies, we customize every protocol to meet your specific research goals.

Contact Us

Are you ready to advance your adrenal cortical carcinoma program with a validated, hormone-responsive in vivo model? Our team of oncology experts is standing by to discuss your specific requirements and provide a detailed project proposal tailored to your timeline. Please reach out to us today via our inquiry form or email to learn more about our NCI-H295R Xenograft Model services.

For research use only. Not intended for any clinical use.